# Episode 53. Belantamab Makes a Comeback with Dr. Hang Quach

Page: https://stenobird.com/podcast/blood-cancer-talks-5570002/episode-53-belantamab-makes-a-comeback-with-dr-hang-quach
Text version: https://stenobird.com/podcast/blood-cancer-talks-5570002/episode-53-belantamab-makes-a-comeback-with-dr-hang-quach.md
Podcast: [Blood Cancer Talks](https://stenobird.com/podcast/blood-cancer-talks-5570002)
Published: 2024-11-13T12:00:00+00:00
Episode link: https://share.transistor.fm/s/5d7e0d35
Audio file: https://media.transistor.fm/5d7e0d35/6a9783a7.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/blood-cancer-talks-5570002/episodes/episode-53-belantamab-makes-a-comeback-with-dr-hang-quach
Duration seconds: 2681

## Resource

In this episode, we discuss the comeback of belantamab mafadotin in multiple myeloma with Dr. Hang Quach, along with some other important abstracts presented at EHA/ASCO 2024. Here are the studies we discussed: 1. DREAMM-7 RCT: Belantamab-Vd vs Daratumumab-Vd in relapsed MM. https://pubmed.ncbi.nlm.nih.gov/38828933/ 2. DREAMM-8 RCT: Belantamab-Pd vs PVd in relapsed MM. https://pubmed.ncbi.nlm.nih.gov/38828951/ 3. Long-term follow-up of CASSIOPEIA Trial: https://pubmed.ncbi.nlm.nih.gov/38889735/ 4. Update on MRD data from PERSEUS Trial: https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.7502

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/blood-cancer-talks-5570002/episodes/episode-53-belantamab-makes-a-comeback-with-dr-hang-quach/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/blood-cancer-talks-5570002/episode-53-belantamab-makes-a-comeback-with-dr-hang-quach.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.